Massachusetts Financial Services Co. MA Has $211.42 Million Stock Holdings in Cencora, Inc. (NYSE:COR)

Massachusetts Financial Services Co. MA reduced its stake in shares of Cencora, Inc. (NYSE:COR) by 21.4% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 940,981 shares of the company’s stock after selling 256,178 shares during the quarter. Massachusetts Financial Services Co. MA’s holdings in Cencora were worth $211,420,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the stock. Meeder Advisory Services Inc. increased its holdings in Cencora by 4.1% in the 4th quarter. Meeder Advisory Services Inc. now owns 4,058 shares of the company’s stock valued at $912,000 after buying an additional 159 shares during the period. Geode Capital Management LLC boosted its position in shares of Cencora by 3.1% during the 4th quarter. Geode Capital Management LLC now owns 4,326,064 shares of the company’s stock worth $969,471,000 after acquiring an additional 130,213 shares in the last quarter. HighPoint Advisor Group LLC increased its stake in Cencora by 4.2% in the fourth quarter. HighPoint Advisor Group LLC now owns 5,299 shares of the company’s stock valued at $1,307,000 after acquiring an additional 215 shares during the last quarter. Franklin Resources Inc. raised its position in Cencora by 1.9% during the fourth quarter. Franklin Resources Inc. now owns 211,076 shares of the company’s stock valued at $47,425,000 after purchasing an additional 3,945 shares in the last quarter. Finally, B. Metzler seel. Sohn & Co. AG lifted its stake in Cencora by 0.9% during the fourth quarter. B. Metzler seel. Sohn & Co. AG now owns 7,389 shares of the company’s stock worth $1,660,000 after purchasing an additional 69 shares during the last quarter. Institutional investors own 97.52% of the company’s stock.

Wall Street Analysts Forecast Growth

COR has been the topic of several recent analyst reports. Evercore ISI lifted their price target on Cencora from $270.00 to $280.00 and gave the company an “outperform” rating in a research note on Thursday, February 6th. StockNews.com raised Cencora from a “hold” rating to a “buy” rating in a research note on Wednesday, March 12th. Wells Fargo & Company boosted their target price on Cencora from $251.00 to $274.00 and gave the stock an “equal weight” rating in a research note on Friday, March 14th. Finally, JPMorgan Chase & Co. raised their price target on shares of Cencora from $289.00 to $301.00 and gave the company an “overweight” rating in a research note on Friday, January 24th. Two analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $280.20.

Insiders Place Their Bets

In other news, EVP Silvana Battaglia sold 5,000 shares of the stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $242.24, for a total value of $1,211,200.00. Following the sale, the executive vice president now directly owns 15,374 shares of the company’s stock, valued at approximately $3,724,197.76. This represents a 24.54 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Robert P. Mauch sold 4,970 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $255.00, for a total transaction of $1,267,350.00. Following the transaction, the chief executive officer now directly owns 51,070 shares of the company’s stock, valued at approximately $13,022,850. This represents a 8.87 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 30,675 shares of company stock worth $8,034,778 in the last quarter. 10.80% of the stock is owned by company insiders.

Cencora Trading Up 3.5 %

Shares of Cencora stock opened at $289.41 on Friday. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92. The stock has a market capitalization of $56.12 billion, a P/E ratio of 41.17, a P/E/G ratio of 1.31 and a beta of 0.51. Cencora, Inc. has a 52-week low of $214.77 and a 52-week high of $291.83. The stock’s 50-day simple moving average is $256.66 and its 200 day simple moving average is $242.38.

Cencora (NYSE:COR) last released its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. As a group, research analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, March 3rd. Investors of record on Friday, February 14th were issued a dividend of $0.55 per share. The ex-dividend date was Friday, February 14th. This represents a $2.20 dividend on an annualized basis and a yield of 0.76%. Cencora’s dividend payout ratio (DPR) is 31.29%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.